Beijing Danatlas Pharmaceutical Technology Co. Ltd. has disclosed poly(ADP-ribose) glycohydrolase (PARG) inhibitors reported to be useful for the treatment of cancer.
J Ints Bio Co. Ltd. has announced research findings with JIN-001, in development in collaboration with MD Anderson Cancer Center, for the treatment of brain tumors.
Researchers from Cogent Biosciences Inc. have presented data on their PI3KA H1047R mutant inhibitor CGT-6297 PI3KA wild-type inhibitors can lead to toxicity issues such as hyperglycemia, gastrointestinal toxicity and skin reactions.
Researchers from KU Leuven presented novel urokinase plasminogen activator receptor-associated protein (uPARAP)-targeted antibody-drug conjugates (ADC), ADCE-017 and ADCE-202, being developed for the treatment of soft tissue sarcoma.
Hemogenyx Pharmaceuticals plc has obtained approval by the institutional review board (IRB) of the company’s first clinical site to initiate a phase I trial of the company’s lead asset, HEMO-CAR-T, for the treatment of relapsed or refractory acute myeloid leukemia (AML) in adults.
Oncobone Ventures Ltd. and Origenis GmbH have signed a framework agreement to develop novel therapies targeting cancer bone metastasis. Origenis leverages its artificial intelligence (AI)-driven technology platform Molmind-Moresystem-Brainstorm to design innovative targeted small-molecule therapies.
Researchers from Caedo Oncology AS presented the discovery and preclinical characterization of CO-005, a novel anti-CD47 fusion protein being developed for the treatment of lymphoma.
Adcendo ApS has closed an oversubscribed $135 million series B financing round to support its development of first-in-class antibody-drug conjugates (ADCs) for the treatment of cancers with a high unmet medical need.
When it comes to cell therapy, Alloplex Biotherapeutics Inc. CEO Frank Borriello said he believes that autologous, personalized therapy is the only thing that makes sense. “The allure of an off-the-shelf therapy has been such a magnet. It sucked in a lot of companies into that dream, and I'm sorry to say, it hasn't really worked out for them,” he told BioWorld. Instead, Borriello said he envisioned a cell training platform that doesn’t just tweak a single immune pathway but instead harnesses multiple immune pathways to turn the tables on cancer.
Many studies have linked the presence of specific bacteria to various diseases. But a general overgrowth of gut bacteria can be a symptom of different conditions, including colorectal cancer and inflammatory bowel disease.
RSS
